Published eLetters
If you would like to comment on this article, click on Submit a Response to This article, below. We welcome your input.
Jump to comment:
- Page navigation anchor for RE: A reduction in burden of diabetes medications, a promotion in management of diabetesRE: A reduction in burden of diabetes medications, a promotion in management of diabetes
The article by Lixin Guo et.al. is an important contribution to evaluation temporal changes in the costs and drugs used for Chinese patients with diabetes. This study is a large-scale retrospective study, which aims to analyze the changes of treatment cost, medication and prescription of diabetic patients in Beijing from 2016 to 2018. In this research, the baseline information of all patients, including age, sex, complications, complications, medical expenses, etc. were extracted, and the personal privacy information was desensitized. The main end-point indicators include the number of outpatient drugs, disease diagnosis, estimated annual outpatient drug costs and commonly used prescription drugs. The medical expenditure of patients with diabetes is less, and the complexity of treatment is also gradually decreasing, which confirms the success of rational treatment options and medical insurance policy for patients with diabetes in Beijing, China.
Show More
There were many strengths worthy of mentioning in the study. First, this research is the first cost analysis of the medical management of diabetes since the implementation of Chinese medical insurance. It is a timely feedback and reminder for us to find the changes in treatment costs and trends in medications prescribed in recent years. The second strength is its enough large sample size fostering confidence in the results. As an observational, retrospective, multi-center study, it was conducted by the team of Guo et al. with...Competing Interests: None declared.